Dear DPA Members,

I am very pleased to invite you to register for our educational program sponsored by Exelixis Biotechnology. This program is exclusively for DPA members, so therefore please do not invite or share registration information to anyone outside of DPA. Space limitation is set by the sponsor and no walk-ins can be accommodated.

You only need to register on the DPA website to attend this program at: https://www.dupagepharmacists.org/

EVENT DETAILS

WHEN: Wednesday, May 20th, 2026, at 6:00 PM

WHERE: Maggiano’s Little Italy, 240 Oak Brook Center, Oak Brook, Il

MEETING AGENDA:

6:00pm – Social Time & Registration

6:30pm-7:15pm – Exelixis Biotechnology – Colorectal Cancer Disease State presented by Tasha Hall, RN, PhD, Executive Medical Affairs Director and Theresa Bui, PharmD, MSL

7:30pm-8:30pm – Continuing Pharmacy Education Program presented by Dr. Eden Keller, PharmD. Dr. Keller is the Assistant Professor at UIC and manages the inpatient substance use disorder service and will be discussing a providers role in Opiod use disorder and harm reduction strategies.

8:30pm-9:00pm – General announcements and introduction of our newly elected Vice President

Presentation 1: Sponsored by Exelixis Biotechnology

Program Title: “Colorectal Cancer Disease State”.

Speaker: Tasha Hall, RN, PhD, Executive Medical Affairs Director and Theresa Bui, PharmD, MSL

Presentation 2: DPA Sponsored Continuing Pharmacy Education

Program Title: A Pharmacist’s Role in Opioid Use Disorder and Harm Reduction Strategies

Speaker: Eden Keller, PharmD, Clinical Assistant Professor | UIC Retzky College of Pharmacy

Educational Objectives:

Target Audience: Pharmacists and Pharmacy Technicians

Pharmacist should be able to:

1. Discuss definition of “addiction” and DSM-5 criteria for substance use disorder
2. Summarize pharmacotherapeutic treatment options for opioid use disorder (OUD)
3. Describe methods to practice harm reduction and work against stigma

Pharmacy Technician should be able to:

1. Discuss definition of “addiction” and DSM-5 criteria for substance use disorder
2. Summarize pharmacotherapeutic treatment options for opioid use disorder (OUD)
3. Describe methods to practice harm reduction and work against stigma